Agoracom Blog Home

Posts Tagged ‘Marijuana’

NORTHBUD $NBUD.ca – Open letter to Ottawa: This one small detail is hindering the #cannabis industry’s success $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 1:48 PM on Wednesday, November 20th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

Open letter to Ottawa: This one small detail is hindering the cannabis industry’s success

The excise stamp on a package of cannabis. Industry leaders say these stamps unique to every province and territory are making it more expensive to produce, package and ship cannabis to individual markets.Darren Brown/Postmedia

The devil is in the details. It’s a common but important refrain. It reminds us how even the smallest facets of plans, processes and situations can derail large-scale efforts.

Such is the case facing Canada’s cannabis industry. The federal government currently requires that all cannabis products carry excise stamps — proof the appropriate taxes have been paid by the licensed producer — like those attached to tobacco packaging. These stamps are also unique to each province and territory.

Excise stamps have been a source of ongoing frustration since legalization

For such a small item, the stamp significantly complicates the business of providing legal cannabis to law-abiding consumers. In addition, excise stamps hinder the flow of legal cannabis across the country, leading to costly supply issues for both governments and consumers.

Excise stamps have been a source of ongoing frustration since legalization. The logistics of applying these stamps has resulted in unnecessary product delays. Likewise, when the industry is criticized for excessive packaging, it’s often the result of complying with federal cannabis packaging requirements, which include provincial/territorial excise stamps.

Logistics aside, the stamps hinder the industry’s long-term success. Requiring producers to use province/territory-specific excise stamps impedes the flow of product across the country. Aside from the complexity of per-province labelling, product that does not sell in one region cannot easily be transported to another province where demand may be higher. The labelling requirement removes licensed producers’ ability to respond in real time to changing demand, adds unnecessary complexity to product forecasting, and means jurisdictions and retailers face completely preventable product shortages. And when consumers can’t find what they want in the legal market, they turn to the unregulated market.

The administrative and production burdens of the stamp also mean that it’s more expensive to produce, package and ship cannabis to individual markets. This means it’s substantially tougher for legal producers and retailers to compete, particularly with respect to price, with the illegal cannabis market, which shoulders absolutely none of the costs imposed on the legal system. One of the primary goals of cannabis legalization was to compete with and thereby eliminate the unregulated market for cannabis. So why do we insist on requirements like a unique provincial/territorial excise stamp that prevents that competition?

The current system isn’t working because it ignores both business and market realities

No one is objecting to industry regulation. Licensed producers have complied with regulatory requirements related to production, distribution and promotion of the product — and have made the financial investments necessary to do so. Province- and territory-specific excise stamps, however, are costly and unnecessary when one national excise stamp would do. Especially in such a new industry, where the efficiency of the manufacturing process is paramount, it is not only counter-intuitive but also counter-productive to continue the practice.

The current system isn’t working because it ignores both business and market realities. We’re not the first industry to come to this realization. In fact, Canada’s alcohol industry moved away from province/territory-specific excise stamps years ago, after delivering its own regulatory impact analysis and successfully arguing the benefits of an alternative approach.

As an industry, we have heard consistently from both public and private retailers across Canada that the current system of unique stamps offers them little to no value. At least one territory has indicated it has asked the Canada Revenue Agency to allow it to use product excise stamps for another province in order to increase its ability to access additional supply. More importantly, CRA has indicated a willingness to work with the industry on a redesign of the excise stamp. That’s progress.

If we are wholly committed to the goals of a thriving industry, we need to alleviate the logistical, financial and environmental burden of monitoring these products while successfully competing with the unregulated market. We can do so in a way that is effective, safe, and benefits the industry as well as Canadian consumers. It’s time to excise multiple excise stamps and move, instead, to a national one.

Terry Booth, CEO, Aurora; Adine Carter, Chief Marketing Officer, Tilray; Nav Dhaliwal, CEO, The Supreme Cannabis Company; Greg Engel, CEO, Organigram; Torsten Kuenzlen, CEO, Sundial Growers; Csaba Reider, President, The Green Organic Dutchman; Irwin Simon, Interim CEO and Board Chair, Aphria; Sebastien St-Louis, President & CEO, HEXO; Mark Zekulin, CEO, Canopy Growth Corporation. The authors are members of the Cannabis Council of Canada, the national industry association representing the legal cannabis sector.

Source: https://business.financialpost.com/opinion/open-letter-to-ottawa-this-one-small-detail-is-hindering-the-cannabis-industrys-success

PRIMO Nutraceuticals Inc. $PRMO.ca – PODCAST: #Hemp, #CBD And #Cannabis With Josh Drayton And Alex Seleznov $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 10:39 AM on Wednesday, November 20th, 2019

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

PODCAST: Hemp, CBD And Cannabis With Josh Drayton And Alex Seleznov

Summary

  • Josh Drayton is Communications and Outreach Director of the California Cannabis Industry Association, an association that collectively represents over 460 industry businesses.
  • Alex Seleznov is a board member and Treasurer for the National Hemp Association as well as founder of Advanced Extraction, a company specializing in organically produced hemp products.
  • They join the show today to discuss why everyone’s paying attention to California, the preventable vaping crisis and what it means to be in the current CBD space.

By Rena Sherbill

Topics include:

  • 6:45 – Josh has worked at CCIA for 4 years. Getting to know cannabis as an economic driver and way of life. Passionate about legalization.
  • 7:25 – Issues with California policy. Looking at the timeline. Legalized medical in 1996 but no state regulations. No statewide framework until 2013, which is when CCIA formed. 2016 adult use passed in California and the past few years have seen medical and adult use regulations being figured out. 55 bills in this year alone. Everyone’s paying attention to California but it takes being incredibly engaged.
  • 9:55 – Licensing supply and demand. Dual licensing system in California (local and state permits). Conflicting regulations in different areas.
  • 11:15 – Regulated vs. illicit shops. Lack of education about black market. Plays into the vaping crisis. Needs to improve. Deaths in California happened in banned areas from black market. War on drugs doesn’t improve public health. Legislators beginning to understand this.
  • 13:35 – Prediction for federal legality. Will California be a model? California modeled itself on other successful markets and has gone above and beyond in regards to packaging and testing regulations. Federal government is watching California. Canada, France, New Zealand, Germany regulators all have toured California to see how their cannabis market works. SAFE Banking Act a huge catalyst. Regulating gives more control, not less.
  • 15:23 – Farm Bill passing, CBD proliferation has helped THC market. Medical conversations help with cannabis and hemp markets.
  • 16:40 – Investors interested in getting into the space – everyone needs to understand it’s a marathon, not a sprint. The longer the legal market exists the more it’s going to pay off.
  • 17:25 – Alex’s company Advanced Extractions. Vertically integrated hemp/CBD company based in Colorado.
  • 18:25 – Confusion around passage of Farm Bill in CBD space. What it means to be in the CBD space right now. Lack of regulation means people are interpreting rules on their own. Lots of opportunity.
  • 19:49 – What do investors and consumers need to look for in this space? Investors need to vet claims a company makes. Only FDA demand is on claims. Transparency is key as well as evidence of regulatory compliance. Market is subject to scrutiny that no other product – no matter how harmful – is subject to.
  • 22:05 – Differentiation in a saturated market. Restricted marketplace gives opportunity for brands to find their niche.
  • 23:52 – Future of hemp space. Total plant purposes of hemp. Putting more renewables into the consumer stream. Alternative to plastic. Initially there will be more of a ceiling before it’s able to become a mass market product.

Source: https://seekingalpha.com/article/4307958-hemp-cbd-cannabis-josh-drayton-alex-seleznov

Empower $CBDT.ca launches #CBD product sales strategy in California and provides progress report on Heritage Joint Venture for Extraction and Production Facility in Oregon $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:39 AM on Wednesday, November 20th, 2019
  • Company has launched commissioned based sales personnel and an influencer strategy for it’s Sollievo CBD line in Southern California
  • In addition, the Heritage CSE: CANN previously announced proposed joint venture initiative, is proceeding forward as planned with the definitive agreement drafting taking place and facility and equipment procurement plans underway.

VANCOUVER, Nov. 20, 2019 - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (OTC: EPWCF) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics in the U.S., is pleased to announce the Company has launched commissioned based sales personnel and an influencer strategy for it’s Sollievo CBD line in Southern California. In addition, the Heritage CSE: CANN previously announced proposed joint venture initiative, is proceeding forward as planned with the definitive agreement drafting taking place and facility and equipment procurement plans underway.

The California population is 39,557,045 people according to the US Census Bureau’s 2018 Population Estimates Program making it the most populated state in the U.S. Los Angeles County, Orange County and Ventura County have a combined population of 14,149,511 consumers making it one of the most densely populated regions of the entire country.

The California Cannabis Portal indicates there are over 170 dispensaries in Los Angeles County that our sales agents are canvassing and bringing Sollievo product samples too. They are also talking to various smoke shops, vape stores and a variety of retail locations that carry CBD products or have expressed an interest to sell CBD products.

“Establishing a retail presence in this area for our Sollievo CBD product lines gives us significant volume potential, but also provides crucial market feedback about branding, product quality and consumer adoption.” said Steven McAuley, Empowers Chairman and CEO. “Gaining direct market feedback, by having our own sales agents on the ground is already proving beneficial.”

Heritage Cannabis JV Update

  • The previously announced Empower Clinics and Heritage Cannabis JV announcement from September 17th, 2019 is continuing forward as planned with a variety of actions being completed by both Parties.

  • Documentation of the Definitive Agreement for the joint venture is underway, and progress is expected to be reported by the Companies in the near future.

  • Graeme Staley, the CEO of Purefarma and Board of Directors member for Heritage Cannabis, completed a site visit of the Sandy, OR facility located on the SE side of Portland, Oregon with Empowers Chairman & CEO Steven McAuley.

  • The site visit solidified the importance of the new 5,000 sq. ft. facility secured by Empower, and the fact that the Oregon Department of Agriculture Hemp Handlers Licence has been issued.

  • Both Empower and Heritage believe operating in a low-cost region like Oregon provides a competitive advantage with direct access to the farming supply chain for the some of the best hemp biomass in the entire country.

  • Local facility and labor costs are competitive on a national scale, and with a skilled and passionate local workforce, the joint venture has the opportunity to provide high quality long-term jobs for the local economy of Sandy, OR, Clackamas County and surrounding regions.

ABOUT EMPOWER

Empower is a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics, operating the Sun Valley Health clinic brand www.sunvalleyhealth.com, for its nine corporate locations and for franchises in the United States. As a CBD product manufacturer under the Sollievo brand, the Company distributes its lines through clinics, online and through retail partners. Extraction operations are currently being developed in the Company’s new extraction facility in Oregon.

ABOUT HERITAGE

The Company is a vertically integrated cannabis provider that currently has two Health Canada approved licenced producers, through its subsidiaries Voyage Cannabis Corp. and CannaCure Corp. both regulated under the Cannabis Act Regulations. Working under these two licences, Heritage has two additional subsidiaries, Purefarma Solutions, which provides extraction services, and BriteLife Sciences that is focused on cannabis based medical solutions. Heritage as the parent Company, is focused on providing resources for its subsidiaries to advance their products or services to compete both domestically and internationally.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empowers patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operational in 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2019/20/c5617.html

CONTACTS: Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARICopyright CNW Group 2019

INTERVIEW: Empower Clinics $CBDT.ca Bucks #Cannabis Downfall With 137% Increase In Revenue, 211% Increase In Patient Visits $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 5:10 PM on Tuesday, November 19th, 2019

Empower Clinics JV Could Generate $US 30,000,000 In Annual Revenue From CBD Extraction … But It Doesn’t End There

With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for.  Add in the fact it is now on a ~ $USD 4,000,000 annualized revenue run rate for 2019 and it becomes the kind of company small cap investors have been dying to find as they watch pretender companies melt away.

But it doesn’t end there.

The Company’s latest Q3 financials show that Empower is in full growth mode, with substantial increases in revenue and patient visits, as well as, big reductions in expenses.  Moreover, Company CEO Steven McAuley says growth will continue full steam ahead in Q4, Q1 and beyond.

But it doesn’t end there. 

CBD extraction has been a key element of the company’s vertical integration. Producing its’ own hemp-derived CBD products for its own massive patient list just makes sense. However, thanks to an LOI (moving towards definitive agreement) to JV with extraction experts Heritage Cannabis, the Company’s 5,000 sq ft facility in Oregon is also planning to serve big brand 3rd party partners in the USA .  Empower brings the infrastructure, Heritage brings the expertise and balance sheet.  The result is a match made in shareholder heaven with initial annual capacity of 6,000 Kg at ~ $US 5,000 per Kg, which adds up to $US 30,000,000 in potential revenue.

We emphasize potential  because nobody has started selling anything yet but the facility is expected to begin producing soon.  However, with a built in patient database and talks already having commenced for white label products, Empower is on its way.  Moreover, “potential” cuts both ways, with capacity capable of increasing 2x – 3x without much trouble given the size of the facility.  

Can Empower successfully execute its extraction plan?  It’s a legitimate question, with a blow away answer..
The Company’s new CEO, Steven McAuley, who replaced the previous management team in January, is Six Sigma certified under the quality initiative of legendary GE chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which also explains how McAuley has brought Empower to such heights in just 11 months.

The cannabis market is currently throwing away babies with the bathwater – but just as the dot-com crash brought us massive riches through Web 2.0 companies that were REAL, investors need to start looking for the REAL companies that will survive and thrive.  With 165,000 patients, rapidly increasing revenues, a franchise plan to grow clinics across America and a vertical integration CBD extraction strategy to tie them all together, Empower Clinics may be such a company.  

Grab your favourite beverage and settle in to watch what may be your next great small cap investment.

North Bud Farms $NBUD.ca Enters U.S. Market with the Signing of the Definitive Agreement to Acquire Nevada Botanical Science Located in Reno, Nevada $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 8:59 AM on Tuesday, November 19th, 2019
  • Signed a definitive asset purchase agreement to acquire all assets of Nevada Botanical Science, Inc.
  • Transaction valued at USD$7.5 million
  • NBS currently operates a 5,000 sq. ft. indoor cultivation facility and has been approved for expansion of up to 60,000 sq. ft of greenhouse space.
  • Property also includes an operating extraction facility and licensed and approved commercial kitchen.
  • This infrastructure is capable of manufacturing and bottling beverages and edibles and is currently used by NBS for both white label and branded product manufacturing.

TORONTO, Nov. 19, 2019 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce that Bonfire Brands USA, a wholly owned subsidiary of NORTHBUD, has signed a definitive asset purchase agreement to acquire all assets of Nevada Botanical Science, Inc. (“NBS”) (see June 25, 2019 press release) in a transaction valued at USD$7.5 million.

Nevada Botanical Science (NBS) is located in Reno, Nevada. NBS holds Nevada State medical and adult use licenses for cultivation, extraction and distribution. NBS operates an integrated cannabis operation located on 3.2 acres of land within the Reno green zone industrial park. NBS currently operates a 5,000 sq. ft. indoor cultivation facility and has been approved for expansion of up to 60,000 sq. ft of greenhouse space. The property also includes an operating extraction facility and licensed and approved commercial kitchen. This infrastructure is capable of manufacturing and bottling beverages and edibles and is currently used by NBS for both white label and branded product manufacturing. Operated by healthcare professionals, NBS has been primarily focused on the Nevada State medical cannabis market. NBS currently manufactures and sells award winning (Jack Herer Cup 2018) topical pain creams, balms and lotions under the Trichomic medical brand.

This past year NBS launched a trial release of cannabis infused cocktails under the brand “Happiest Hour”. Collaborating with local craft beverage manufactures NBS released a variety of beverages including Margarita, Pina Colada, Bloody Mary, Long Island Ice Tea and Lemonade to select retailers in the state. To date retailer adoption and reordering has been 100% and based on customer feedback, NBS will increase production and distribution including additional retailers in Las Vegas in 2020. NBS has also finished a successful trial launch of its energy shot 1oz beverage containing 25mg of THC and 50mg of Caffeine. The Company plans to run a second branded trial in early 2020. Over the past three months NBS and NORTHBUD have been working together in preparation for the release of NORTHBUD branded dried flower products in Q4 2019 and a variety of infused and non-infused pre rolls. 

“Subject to the finalizing of the previously announced acquisition of the Qlora Group in California, the Company plans to establish a unified product manufacturing and distribution platform within these two important states,” said Justin Braune, President of Bonfire Brands USA. “The license classes in California and Nevada allow for identical activities and the Company has been in negotiation with multiple potential JV partners who wish to leverage this unique platform. Being one of the few multi state operators with operations in both states will allow us to offer turnkey solutions to prospective partners moving forward.”

Transaction Terms

The transaction (the “Transaction”) is structured as an asset purchase agreement whereby in exchange for the purchase of all of the securities and assets of NBS, NORTHBUD is paying a total of USD$7,500,000 as follows:

  • Cash payment of USD$500,000 (paid in full);
  • Approximately USD$1 million in convertible shares of Bonfire Brands USA (6,500,000 “convertible shares”); and
  • A USD$6,000,000 interest bearing promissory note.

The convertible shares may be exchanged on a 1-1 basis with common shares of NBUD at the discretion of the shareholder. At the time of signing, the converted value of these securities was equal to USD$1,000,000. All applicable U.S. and Canadian regulatory holds shall apply upon conversion.

As per the terms of the agreement NBS will allocate pro rated ownership of assets in NBS and all associated licenses to Bonfire Brands USA throughout the re-payment period, subject to state approval.

Bonfire Brands and NBS have agreed to an operations and management arrangement allowing Bonfire to assume operational control, begin integration and driving revenue immediately.  

“The NORTHBUD and Bonfire Brands USA team are extremely proud to have finalized this agreement making the state of Nevada our strategic entry point into the U.S. legal cannabis market,” said Ryan Brown, CEO of NORTHBUD. “We are equally proud of the structure of the deal and how it minimizes shareholder dilution while allowing our team to begin integration and operations with a focus on immediate revenue growth in one of the most sought-after adult use markets in North America. Our team has been looking at acquisitions in Nevada for over two years before finding the right fit.  The Nevada market is considered one of the largest and most profitable in North America with recreational sales of USD$580 million in the first full year of legalization* (2017 Nevada Dept. of Taxation).”

The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The Transaction is a significant acquisition but will not result in a “Fundamental Change” pursuant to the policies of the CSE. NORTHBUD will be preparing the necessary corporate and securities filings in order to secure the required approvals for the Transaction.

The parties have agreed to pay USD$187,500 in broker/finder fees to arm’s length parties on a prorated basis connection with the closing of the Transaction.

The closing of the Transaction is conditional on the receipt by the parties of applicable corporate and regulatory approvals, including that of the CSE.

About Nevada Botanical Science, Inc.

Founded by a group of northern Nevada physicians and healthcare professionals who believe in the promise of medical cannabis, Nevada Botanical Science has developed a world class cannabis production, research and development facility in Reno’s Washoe County. Its work and commitment are fully in compliance with the Hippocratic Oath as well as Nevada statute. Nevada Botanical Science is dedicated to ensuring the highest measure of safety, governance and stewardship for its patients, employees and the community it serves.

For more information visit: www.nevadabotanicalscience.com

About North Bud Farms Inc.

North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act.  The Company has built a state-of-the-art purpose-built cannabis production facility located on 135 acres of Agricultural Land in Low, Quebec, Canada. NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA has acquired Nevada Botanical Science, Inc. a world class cannabis production, research and development facility with 5,000 sq. ft. of indoor cultivation in Reno’s Washoe County. Nevada Botanical Science holds medical and adult use licenses for cultivation, extraction and distribution. Bonfire Brands USA has entered into an agreement to acquire assets in Salinas, California.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation.  Forward-looking statements, including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. This press release contains forward- looking statements including those relating to the entering into of the Definitive Agreement and closing of the Transaction with Nevada Botanical Science, Inc. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, the risk factors included in the Company’s final long form prospectus dated August 21, 2018, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

NORTHBUD $NBUD.ca – #THC – infused #edibles and #CBD – infused edibles $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 5:37 PM on Monday, November 18th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

THC-infused edibles and CBD-infused edibles

When cannabis is ingested, the THC is metabolized by the liver

With edibles coming to brick-and-mortar shops in mid-December, users are looking to get high without the smoke.

But when choosing edibles, users will want to pay attention to whether the product has CBD or THC, two compounds with very different effects.

CBD

CBD, the non-psychoactive component within cannabis has been widely touted for its medical benefits to help people with, among other conditions, chronic pain. The World Health Organization (WHO) reports CBD is not physically addictive.

By comparing those administered doses of active CBD to those given as a placebo, researchers said that “while the number of studies is limited, the evidence from well-controlled human experimental research indicates that CBD is not associated with abuse potential.”

CBD leads to slower effects that aren’t psychoactive in nature — meaning they aren’t the effects you see portrayed in pop culture.

The effects from CBD will be tame and mellow compared to its psychoactive opposite, THC. Most medical cannabis includes CBD rather than THC, with CBD already available in capsule form in legal stores.

THC

When most people think of cannabis’ effects, they think of THC. Many of the new cannabis products slated to enter stores in mid-December will focus on THC.

When cannabis is ingested, the THC is metabolized by the liver, transforming itself into 11-hydroxy-THC. This metabolite is up to four times faster in crossing the blood-brain barrier than average THC, and is why edibles are associated with intense, vivid and longer-lasting experiences.

THC normally gets pointed at as the compound that creates the potential for withdrawal symptoms among some heavy users.

An evidence brief compiled by the Canadian Public Health Association (CPHA) states that “cannabis is addictive, though not everyone who uses it will develop an addiction.”

While using cannabis oil or edibles with THC, users may get addicted or experience habit-formation. Products that only include CBD don’t appear to become addictive.

Source: https://lfpress.com/cannabis-news/day-29-thc-infused-edibles-and-cbd-infused-edibles/wcm/473a4264-5028-4c42-94ca-53da8b2db7c7

CLIENT FEATURE: Vertical Exploration $VERT.ca – Note Facility to Support Development at St-Onge Paving the Way for Wollastonite Exploitation $TORR.ca $FA.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM at 12:25 PM on Monday, November 18th, 2019
http://www.smallcapepicenter.com/Vert%20Square.png
VERT: v –

Vertical Exploration and Venturevest Realty Partners LLC have signed a non- binding Letter of Intent (LOI) to enter into discussions regarding a secured Note Facility up to a maximum amount of $20 million CAD to support the multi-phased development of the St-Onge Wollastonite Deposit.

A staged credit facility allowing Vertical to move forward with four distinct phases of St-Onge development, first establishing the initial quarry style permitting and production phase through to the mining and final processing plant stage.

https://vertxinc.com/wp-content/uploads/2018/01/Bitmap.png

What is Wollastonite?

  • Wollastonite is a chemically simple mineral named in honor of English mineralogist and chemist Sir W.H. Wollaston (1766–1828). It is composed of calcium (Ca) and silicon and oxygen (SiO2, silica) with the chemical formula CaSiO3. Although much wollastonite is relatively pure CaSiO3, it can contain some iron, magnesium, manganese, aluminum, potassium, sodium, or strontium substituting for calcium in the mineral structure. Pure wollastonite is bright white; the type and amount of impurities can produce gray, cream, brown, pale-green, or red colors.

Wollastonite’s Many Uses

Cannabis Research:

  • Wollastonite has already many well-known benefits in agriculture
  • Testing in a controlled way for the use in the cannabis industry.
  • Possibly the first in the industry to do trials.
  • Engaged AGRINOVA for Wollastonite Research and Development
  • Entered into a Distribution Agreement with AREV Brands, where Vertical will supply its St-Onge wollastonite to AREV for direct distribution to both small-scale craft growing operations and potentially larger-scale Health Canada approved companies directly involved in growing and processing cannabis and hemp.
  • Testing of Vertical’s St-Onge wollastonite on a range of important agricultural end uses will also be conducted
  • Became a member of the International Fertilizer Industry Association (IFA), as part of its ongoing efforts to promote and strategically market it’s world-class St-Onge wollastonite to a range of potential end-users.

Major Demand in Ceramics Industry:

  • Combination of high brightness and low gas release of Wollastonite when heated creates demand
  • Brilliant whiteness of importance to coatings and filler markets

Wollasatonite applications are endless

  • An industrial mineral comprised chemically of calcium, silicon and oxygen. Its molecular formula is CaSiO3 and its theoretical composition consists of 48.28% CaO and 51.72% SiO2.

St. Onge Wollastonite Deposit 2019

  • Twenty-three (23) drill holes totaling 1,784.0 metres were completed
  • Twenty (20) drill holes intersected high-grade wollastonite zones, confirming excellent continuity and correlation with the thickly mineralized zones intersected by previously reported historical drill holes.
  • Sixteen (16) drill holes intersected high-grade wollastonite zones right up until the end of the hole, which are all open at depth.
  • A total of 1,107.5 meters of high-grade wollastonite mineralized core length was intersected, representing approximately 62% of all drilled core length.

PRIMO Nutraceuticals Inc. $PRMO.ca – Feds Finally Crafting National #CBD Rules $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 5:05 PM on Friday, November 15th, 2019

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

Feds Finally Crafting National CBD Rules

  • After years of states passing their own rules concerning cannabidiol – more commonly known as CBD – the federal government is now quietly taking the first steps to regulate it.

By: Louis Biscotti

Photo: Sven Hoppe/dpa (Photo by Sven Hoppe/picture alliance via Getty Images) dpa/picture alliance via Getty Images

The F&B industry is ahead of them: You can already get CBD in gummies, oils, lotions and juices, and Arizona Iced Tea and Ben and Jerry’s have been testing it. But as states moved to regulate, the federal government sat on the sidelines, leaving CBD in legal limbo.  That began to change a couple of weeks ago in what could be the beginning of the biggest change for the CBD market since the Farm Bill of 2018 ended classifying hemp and products derived from it as controlled substances.

The United States Department of Agriculture (USDA) in late October published its interim final rules for domestic hemp production in the Federal Register, including rules regarding CBD, a product of hemp. How big a deal could this be? Think about the end of Prohibition. The federal government is finally creating standards that could help create a national marketplace. That could help move CBD from the margins to the mainstream, adding security, safety and consistency to manufacturing.

The proposed rules come as sales of CBD are expected to reach $13 billion this year, even as federal law tries to catch up with demand. CBD is getting too big to be ignored, and lack of reliable information and uniform regulation adds to confusion. The feds are finally arriving on the scene (let’s not call it a party) with the structure that’s needed.

The new rules would include federal aid for hemp farmers and could help ease access to insurance and loans, leading to bigger supply and more financing. There are also tough provisions, which could be good for consumers and companies, but will add costs for manufacturers and others in the supply chain. Hemp samples, for instance, would have to be delivered to DEA-certified labs 15 days before harvest and certified.

The USDA, however, is only the first federal agency to lay its hands on hemp and CBD. The Food & Drug Administration (FDA), which approved seizure drug Epidolex containing CBD, classifies it as an active ingredient in medications – which it regulates. The agency in late October said it’s continuing “to explore potential pathways for various types of CBD products to be lawfully marketed.” Manufacturing isn’t currently subject to FDA review. The USDA’s actions could help change that. The Grocery Manufacturers Association, for instance, is pushing for the FDA to issue final CBD rules instead of allowing “a maze of inconsistent, and often contradictory, state and local regulations” that can lead to a “regulatory mess.”

The USDA has also begun to regulate THC, the psychoactive ingredient in hemp sometimes included with CBD. The USDA indicates that, potentially, hemp could contain up to 0.3 percent THC or tetrahydrocannabinol, the limit in Canada and many other countries. The FDA is likely to fall in line with that as CBD becomes more common.

CBD’s popularity comes with often-exaggerated claims; some people look at it as a cure-all. That also could change with regulation. The FDA already issued warnings to companies making medical claims. As the feds begin to regulate CBD, some misinformation may vanish from marketing, which could lower sales, as the market sorts itself out, “weeding out” certain companies as others grow.

Money is already flowing into companies working with CBD. Altria, parent of cigarette giant Philip Morris, poured $1.8 billion into cannabis company Cronos Group. Beer distributors and Arizona Iced Tea are infusing drinks with CBD, hoping to experience (puns are just too easy here) higher sales. As the market for CBD continues to expand, it’s only a matter of time before CBD gets what the Grocery Manufacturers Association wished for: federal regulation.

While most industries dread regulation, it could prove essential for CBD to truly take off in food and beverage, providing safety to consumers and security for producers. The USDA has stepped off the sidelines, and the FDA is talking about stepping in. It looks like federal rules may finally be arriving, bringing standards and — get ready — red tape (which means compliance costs)  in a trade-off for quality control, consumer protection, and growth prospects. It’s starting to look like a national marketplace for CBD may no longer be a pipe dream.

Source: https://www.forbes.com/sites/louisbiscotti/2019/11/15/feds-finally-crafting-national-cbd-rules/#7a79898f1b89

Empower Clinics $CBDT.ca – The case for treating #PTSD with #cannabis $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 1:55 PM on Thursday, November 14th, 2019

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics
  • Patient database of over 165,000 patients 
  • Platform generating $4MM USD in revenue annually (2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Launching CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.

The case for treating PTSD with cannabis

  • Previous research has linked cannabis use with poorer mental health in PTSD patients, but it’s unclear whether cannabis exacerbates PTSD symptoms, or if patients with worse symptoms are simply self-medicating more.
  • Much of he existing evidence for cannabis as a PTSD treatment comes from patient reports of success.

Research shows that cannabis use by people living with post-traumatic stress disorder may reduce their likelihood of depression and suicide

Stock photo This article, written by Stephanie Lake, University of British Columbia and M-J Milloy, University of British Columbia, originally appeared on The Conversation and has been republished here with permission:

Post-traumatic stress disorder (PTSD), a psychiatric condition linked to surviving or witnessing a traumatic life event, will affect around one in 10 Canadians at some point in their lives. PTSD can cause agitation, flashbacks, impaired concentration and memory, insomnia and nightmares and these symptoms can increase the risk of substance abuse and dependence, depression and suicide.

Many patients struggle to find adequate symptom relief from conventional treatments for PTSD including anti-depressant or anti-psychotic medications and psychological treatments such as trauma-focused cognitive behavioural therapy.

Unsurprisingly, many turn to alternative ways of coping — such as medical cannabis use. This is especially evident in the dramatic rise in number of Canadian military veterans receiving government reimbursement for medical cannabis, with PTSD as a common reason for use.

The results of clinical trials testing cannabis as a PTSD treatment are pending. Previous research has linked cannabis use with poorer mental health in PTSD patients, but it’s unclear whether cannabis exacerbates PTSD symptoms, or if patients with worse symptoms are simply self-medicating more. Much of the existing evidence for cannabis as a PTSD treatment comes from patient reports of success.

As epidemiologists and substance use researchers, we have been exploring the relationship between cannabis and PTSD using readily available Statistics Canada mental health data.

In a recent study, published in the Journal of Psychopharmacology, we found that PTSD increased the risk of major depressive episodes among Canadians who didn’t use cannabis by roughly seven times, and suicidal ideation by roughly five times. But, among Canadians who did use cannabis, PTSD was not statistically associated with either outcome.

How cannabis works in the body

Substance use, including cannabis use, is common among trauma survivors. It’s easy to write off the drug as just a tool to briefly escape negative feelings, at the risk of worsening longer-term symptoms. However, the relationship between cannabis and PTSD is more complex than it appears on the surface.

Our bodies naturally produce molecules called endogenous cannabinoids that fit into special cannabinoid receptors throughout the brain and body. This endocannabinoid system is involved in stabilizing bodily processes, including regulating many functions of the brain that tend to be affected after traumatic experiences, such as fear, memory and sleep.

Certain components of the cannabis plant, including the well-known molecules tetrahydrocannabinol (THC, the component of cannabis that produces the high) and cannabidiol (CBD, the component of cannabis that won’t get you high, but has potential for treating epilepsy, inflammation, nausea and anxiety) are also cannabinoids because of their structural similarity to endogenous cannabinoids.

Even though THC and CBD aren’t naturally produced in our bodies, they can interact with the endocannabinoid system to influence a number of biological processes.

Research is still uncovering if and how cannabis works within the body to affect the course of PTSD. Brain imaging research suggests that patients with PTSD have an abundance of cannabinoid receptors but produce few endogenous cannabinoids to lock into them, meaning that supplementing the body with plant-based cannabinoids like THC might help some brain processes function as normal.

Reduced depression and suicide

Roughly one in four individuals with PTSD in the Statistics Canada survey data that we analyzed used cannabis, compared to about one in nine in the general population.

In our study, we used statistical models to quantify the relationship between having PTSD and recently experiencing a major depressive episode or suicidal ideation. We hypothesized that if cannabis helped mitigate symptoms of PTSD, we’d see a much weaker association between PTSD and these indicators of mental distress in the cannabis-using population.

Indeed, exploring the associations in this way while controlling for other factors (such as sex, age, income, other substance use, other mental health problems) supported our hypothesis.

In a follow-up analysis of the 420 individuals in the sample who had PTSD, we categorised cannabis use into “no use,” “low-risk use” and “high-risk use” (meaning that they screened positive for cannabis abuse or dependence).

We found that low-risk cannabis users were actually less likely than non-users to develop a major depressive episode or to be suicidal, though there was a trend towards increased risk of both outcomes for the high-risk users.

A promising new signal

People with PTSD are more likely to experience depression and suicidal ideation. However, our findings suggested that these indicators of mental health were improved when they were engaging in lower-risk cannabis use.

Our study has a number of limitations that prevent us from being able to understand whether cannabis is what’s causing the reduced association between PTSD, depression and suicide.

For example, our data captures information covering participants’ experiences from the previous year, meaning we can’t actually decipher what came first: the cannabis use, the PTSD or the major psychological episodes.

We didn’t have detailed information about how participants used cannabis: for example, the type and dose of cannabis they used, how often they used it or how they consumed it. These details will be crucial to future research in this area.

Our study’s strength comes from its ability to describe patterns of PTSD symptoms and cannabis use in a large sample that’s considered to be representative of the Canadian population. Although our findings suggest that cannabis could be of possible therapeutic use in the treatment of PTSD, cannabis use is not without risks, including the development of cannabis use disorder.

We’ve uncovered a promising new signal on the potential of cannabis-based therapies, but we look forward to much work ahead in understanding how they might fit into PTSD and mental health treatment more broadly.

Source: https://www.collingwoodtoday.ca/local-news/canada-the-case-for-treating-ptsd-with-cannabis-1831760

Empower Clinics $CBDT.ca Reports Q3 2019 Results Highlighted by a 137% increase in clinic revenues compared to Q3 2018 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:23 AM on Thursday, November 14th, 2019
  • 5,807 patient visits generated revenue of $663,003, compared to 1,864 patient visits that generated $279,850 for Q3 2018.
  • Cash used in operating activities improved by $1,309,913 from $3,129,583 for YTD 2018, compared to $1,819,670 for YTD 2019.

VANCOUVER, Nov. 14, 2019  - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (OTC: EPWCF) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics in the U.S., has filed today its unaudited condensed interim consolidated financial statements for the three and nine months ended September 30th, 2019 and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

“Our focus on operational excellence and cost controls are key contributors to strong year-over-year growth numbers and the reduction in direct clinic expense, as we continue to serve the 165,000 patients in our database,” said Steven McAuley, Empowers Chairman & CEO. “The Company is beginning to fulfill its promise of vertical integration with the build-out of the extraction and production center in Portland, OR plus with an increased focus on our proprietary CBD product lines and diversified clinic revenues, the Company has a clear path of growth and profitability going forward.”

Q3 2019 Highlights

  • 5,807 patient visits generated revenue of $663,003, compared to 1,864 patient visits that generated $279,850 for Q3 2018.

  • Net loss of $504,531, compared to $378,657 for Q3 2018, which was primarily driven by increased revenues and fair value adjustments offset by net increased in operating expenses related to the operations of Sun Valley.

  • Cash used in operating activities improved by $1,309,913 from $3,129,583 for YTD 2018, compared to $1,819,670 for YTD 2019.

  • Cash at September 30, 2019 of $178,578, compared to $157,668 at December 31, 2018, which was primarily driven by debt and equity financings during the nine months ended September 30, 2019 and partially offset by cash used in operations, the cash investment in Sun Valley and cash investment in Sun Valley Health Franchise launch.

Highlights

  • Strategic redirection: The Company has been re-positioning its overall strategy to become a vertically integrated health and wellness brand that connects to its 165,000 patients using a data driven focus to improve patients’ lives with products, technology and health systems.

  • Experienced and Seasoned Board of Directors: The Company Board of Directors includes its CEO Steven McAuley, Dustin Klein, the Co-Founder of Sun Valley Clinics and the SVP, Business Development and Andrejs Bunkse, owner and practicing attorney of Rain Legal and Counsel to numerous cannabis enterprises in the U.S. and Canada.

  • Strategic Development: The Company has opened its first hemp-derived CBD extraction facility in greater Portland, Oregon with the first extraction system expected to have the capacity to produce 6,000 kg of extracted product per year. The Company took possession of the new extraction facility June 1st, 2019 and has been awarded it’s hemp-handlers licence from the Oregon Department of Agriculture, allowing the Company to enter the next phase of build-out and full operations in 2019. The Company expects preliminary production of its Sollievo CBD line to take place in the extraction center in 4Q 2019.

  • Strategic Partnership: The Company has entered into a Letter of Intent (“LOI”) to form a Joint Venture Partnership (“JV”) with Heritage Cannabis Holdings Corp (CSE: CANN) (“Heritage”). Terms of the LOI have Empower and Heritage each with a 50% ownership of the JV. Heritage will install extraction units and related downstream extraction equipment inside Empower’s existing licenced hemp processing facility in Sandy, Oregon. Once operational, the JV will begin producing proprietary branded products for Empower’s clinics and third party partners for distribution in the United States.

2019 Outlook and Catalysts

  • Enhanced Corporate Governance: The Company has prioritized corporate governance practices under the leadership of its Board of Directors and Chairman Steven McAuley, to ensure financial and accounting controls operate at the highest of standards.

  • Improved Capital Markets Profile: Empower is diversifying its business model to become a vertically integrated operator in the global cannabis sector with a focus on patient care, CBD product distribution, research & development and CBD product extraction. The Company believes this will appeal to a broader base of shareholders and investors and provide greater access to capital and improved trading liquidity.

  • Increased Patient Access: With a rapidly expanding company-owned clinic network and significant expansion opportunity through the Sun Valley Health franchise model, Empower anticipates it will grow its total patient list substantially in the years ahead. This is expected to provide greater opportunity for treatment analysis using artificial intelligence (AI), through progressive initiatives that include adding the Endocanna DNA test kit to the Company product & service offering in clinics and online. Ensuring the Company is a leader in understanding the efficacy of cannabis-related treatment options is an imperative.

  • Focus on CBD Product Sales: The Company has launched its online store to sell its lines of hemp-derived CBD based products and premium health & wellness supplements. Customers can purchase products, including CBD lotions, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet-elixir hemp extract drops. Patients and customers will be able to access Sun Valley Health customer service, home delivery and e-commerce platforms.

  • Market Leading Technology: Empower utilizes market-leading patient electronic management and POS system that is HIPAA compliant and provides deep insight to patient care. The Company supports remote patients using its tele-medicine portal, enabling patients who do not live near one of its clinic locations, or are disabled or unable to come to a location, to still benefit from a doctor consultation.

  • New Modalities and Services: The Company has launched new physician based modalities and services into the Sun Valley Health clinics and has commenced booking appointments and providing the new services. Each of these services provides the opportunity for increased patient retention, higher revenue per patient visit and increased patient visits per year. The new services include:

    • Physician’s CBD Enhanced Massage, Acupuncture, or Cupping Sessions

    • CBD-Cannabis-Supplement Consumption & Coaching Consultation

    • Introduction to Alternative Health and Cannabinoid Therapies by a Physician

    • Comprehensive Naturopathic Patient Analysis & Consultation

    • Dietary Antigen Testing, Physician Consultation/Action Plan, & Concierge Blood Draw

    • Neurotransmitter (urine) Profile & Physician Consultation/Action Plan

    • Spectracell Micronutrient Test & Physician Consultation/Action Plan
  • Launches Nationwide Franchise: The Company has launched its nationwide franchise program under the Sun Valley Health brand to dramatically grow our clinic & store footprint increasing direct access to patients and to sell hemp-derived CBD products and premium wellness products directly to our customers and online at our new e-commerce store at www.sunvalleyhealth.com

Financial Summary

  $, except patient visits Three months ended September 30, Nine months ended September 30,
  2019 2018 2019 2018
Patient visits 5,807 1,864 11,304 6,293
Clinic revenues 663,003 279,850 1,406,872 894,477
Direct clinic expenses (55,397) (88,956) (177,560) (301,392)
Loss from operations (843,897) (405,048) (2,547,276) (3,716,474)
Net loss (504,531) (378,657) (2,359,579) (5,132,848)
Net loss per share (0.00) (0.01) (0.02) (0.09)

Financial Performance

Clinic revenues for Q3 2019 were $663,003, compared to Q3 2018 revenues of $279,850. This increase over the prior year is attributable to the acquisition of Sun Valley Clinics.

Direct clinic expenses for Q3 2019 were $55,397, compared to Q3 2018 direct clinic expenses of $88,956. These expenses declined despite the increase in revenues due to improved operational controls to align labor cost with direct patient consultations. The Company employs a diverse mix of physicians and practitioners.

Net loss from operations for Q3 2019 was $843,897, compared to Q3 2018 net loss of $405,048. This increase in loss over prior year is primarily attributable operating expenses increasing due to timing of recognition of the expense associated with non-cash share-based awards to management.

Net loss for Q3 2019 was $504,531, respectively, compared to Q3 2018 net loss of $378,657. This increase over prior year is primarily attributable to the increase in operating expenses as noted above, which was partially offset by gains on change in fair value of the conversion option of convertible debentures and warrants.

During Q3 2019, the Company used $1,819,670 in cash from operations after changes in non-cash working capital. The Company invested $629,636 for the acquisition of Sun Valley Clinics and raised $2,470,216 via proceeds from various issuances of shares, convertible debentures and notes.

Please refer to the Company’s unaudited condensed interim consolidated financial statements, related notes and accompanying management discussion and analysis for a full review of the operations.

ABOUT EMPOWER

Empower is a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics, operating the Sun Valley Health clinic brand www.sunvalleyhealth.com, for its nine corporate locations and for franchises in the United States. As a CBD product manufacturer under the Sollievo brand, the Company distributes its lines through clinics, online and through retail partners. Extraction operations are currently being developed in the Company’s new extraction facility in Oregon.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operational in 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2019/14/c6801.html

Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARICopyright CNW Group 2019